Rezolute Inc RZLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
-
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
-
Rezolute to Participate in Upcoming Investor Conferences
-
Rezolute Application for Hypoglycemia Treatment Gets FDA Clearance
-
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
-
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Trading Information
- Previous Close Price
- $4.59
- Day Range
- $4.52–4.73
- 52-Week Range
- $0.72–6.10
- Bid/Ask
- $4.56 / $4.80
- Market Cap
- $260.79 Mil
- Volume/Avg
- 101 / 328,943
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.rezolutebio.com
Comparables
Valuation
|
Metric
|
RZLT
|
PTGX
|
JANX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 16.79 | — |
Price/Book Value | 2.07 | 4.88 | 3.45 |
Price/Sales | — | 8.72 | 140.72 |
Price/Cash Flow | — | 13.96 | — |
Price/Earnings
RZLT
PTGX
JANX
Financial Strength
|
Metric
|
RZLT
|
PTGX
|
JANX
|
|---|---|---|---|
Quick Ratio | 13.21 | 13.60 | 57.02 |
Current Ratio | 13.39 | 13.73 | 57.34 |
Interest Coverage | — | — | — |
Quick Ratio
RZLT
PTGX
JANX
Profitability
|
Metric
|
RZLT
|
PTGX
|
JANX
|
|---|---|---|---|
Return on Assets (Normalized) | −52.02% | 44.65% | −4.75% |
Return on Equity (Normalized) | −57.81% | 49.43% | −5.12% |
Return on Invested Capital (Normalized) | −61.20% | 44.16% | −9.37% |
Return on Assets
RZLT
PTGX
JANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hnljgsld | Qyl | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zjzhtfwc | Rxrhdf | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dlgptpvvp | Dwpfh | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jpyfkcls | Lklqrh | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Ljbpytck | Twy | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Hdgpnbqqk | Wyzmh | $28.3 Bil | |||
| Moderna Inc
MRNA
| Qbwnfsn | Bkgr | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Wfxyflclt | Cjy | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dqchvyhy | Tsqfzc | $13.3 Bil | |||
| Incyte Corp
INCY
| Xfqrnbqy | Rnmlxh | $13.0 Bil |
United States